AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Core Insights - The article discusses AbbVie (ABBV) and highlights its strong buy potential due to the expansion of Rinvoq and the addition of its immunology pipeline [2]. Company Overview - AbbVie is positioned favorably in the biotech sector, with a focus on long-term value generation through its healthcare investments [2]. Analyst Background - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis and a model portfolio of small and mid-cap stocks [2].